PRESS RELEASE
27 November 2026 07:30:00 CET

Cereno Scientific

Cereno Scientific appoints Anders Svensson as Acting Chairperson of the Board – Nomination Committee reviews Board composition

Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that the Nomination Committee is reviewing the composition of the Company's Board of Directors. The Board has appointed Anders Svensson as Acting Chairperson of the Board to ensure continuity and stability in the work of the Board.

Anders Svensson has been a member of Cereno Scientific's Board of Directors since 2018, contributing his extensive expertise in international drug development and cardiovascular medicine. With nearly 20 years of experience in senior positions within the global pharmaceutical industry, including at Roche and AstraZeneca, as well as a strong scientific and clinical background, Anders brings valuable expertise to Cereno's continued development.

His deep understanding of the Company's operations, strategy and clinical development programs, combined with his international experience in drug development, is an important asset at Cereno's current stage of development.

Sten R. Sörensen, CEO and Board member of Cereno Scientific, commented: "Anders has been a highly valued member of Cereno's Board of Directors for many years. His extensive experience in global drug development and deep expertise in cardiovascular medicine are of significant value to the Company. I am very pleased that Anders is now taking on the role of Acting Chairperson of the Board. Together, we remain focused on executing our financing plans and advancing our clinical development programs."

Next steps

In light of the recent changes to the Board of Directors, the Nomination Committee is reviewing the Board's composition, taking into account the Company's current and future needs. The Nomination Committee's proposal will be announced as soon as possible.

An Extraordinary General Meeting will be held to consider the Nomination Committee's proposal and decide on the composition of the Board of Directors. The notice of the Extraordinary General Meeting will be published separately.

For further information, please contact:
Tove Bergenholt, Head of IR & Communications
Email: **tove.bergenholt@cerenoscientific.com**
Phone: +46 73- 236 62 46

Cereno Scientific

About Cereno Scientific AB
Cereno Scientific is pioneering treatments to enhance and extend life. The company's innovative pipeline offers disease-modifying drug candidates to empower people suffering from rare cardiovascular and pulmonary diseases to live life to the fullest.

Lead candidate CS1 is an HDAC inhibitor that works through epigenetic modulation and represents a novel therapeutic approach by targeting the underlying mechanisms of pulmonary arterial hypertension (PAH). CS1 is a well-tolerated oral therapy with a favorable safety profile that has shown encouraging efficacy signals in a Phase IIa trial in patients with PAH, including improvements in right heart function, functional class, risk score and patient quality of life, with early signs consistent with reverse vascular remodeling. An Expanded Access Program confirmed CS1 to be well-tolerated with a favorable safety profile over 12 months of treatment and showed that a majority of patients completing treatment maintained or improved clinical status. CS1 is currently being evaluated in EPIMODE, a global, placebo-controlled Phase IIb trial in PAH. CS014 is a new chemical entity and HDAC inhibitor with a multimodal mechanism of action as an epigenetic modulator having the potential to address the underlying pathophysiology of a range of cardiovascular and pulmonary diseases with high unmet needs. CS014 showed a favorable safety and tolerability profile in Phase I, and is being advanced through a streamlined, FDA-aligned pathway toward Phase IIb in pulmonary hypertension associated with interstitial lung disease (PH-ILD). Cereno Scientific is also advancing the preclinical program CS585, an oral, highly potent and selective prostacyclin (IP) receptor agonist shown to prevent thrombosis without increased bleeding risk, currently being evaluated in antiphospholipid syndrome (APS).

The Company is headquartered in GoCo Health Innovation City in Gothenburg, Sweden, and has a US subsidiary, Cereno Scientific Inc., located in Kendall Square, Boston. Cereno Scientific is listed on the Nasdaq First North (CRNO B). The Company's Certified Adviser is DNB Carnegie Investment Bank AB, **certifiedadviser@carnegie.se**. More information can be found on **www.cerenoscientific.com**.